Zetagen Therapeutics Presents Phase 2a Results at ASCO for Investigational ZetaMet™ (Zeta BC 003) in Metastatic Breast Cancer Patients with Lytic Bone Lesions
A single intratumoral injection resulted in no reported skeletal‑related events (SREs) or fractures No treatment‑emergent adverse events (AEs) or serious adverse events (SAEs) Cessation of tumor activity, along with reduction in pain scores, and opioid consumption Therapeutic effect observed in adjacent, non‑injected lesions within the treated vertebral body AUSTIN, Texas — Zetagen Therapeutics, a clinical‑stage […]
Original Source
Read the full article at Financialpost →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.